Organ-sparing treatment of advanced bladder cancer: Paclitaxel as a radiosensitizer

Arndt Christian Müller*, Andrea Diestelhorst, Thomas Kuhnt, Reinhard Kühn, Paolo Fornara, Hans Jörg Scholz, Jürgen Dunst, Anthony Laurence Zietman

*Korrespondierende/r Autor/-in für diese Arbeit
23 Zitate (Scopus)


Background and Purpose: Transurethral resection of bladder tumor (TUR-BT) and radiochemotherapy with cisplatin achieve high rates of bladder preservation and survival figures identical to radical cystectomy in muscle-invasive bladder cancers. The authors have investigated the potential use of paclitaxel in a radiochemotherapy protocol for patients with inoperable bladder carcinomas and mainly contraindications to cisplatin. Patients and Methods: Between October 1997 to August 2004, 42 patients (median age 71 years) suffering from muscle-invasive (n = 32) or recurrent (n = 10) bladder cancers were treated with a paclitaxel-containing radiochemotherapy (paclitaxel 25-35 mg/m2 twice weekly) after TUR-BT (R0/1/2/x in n = 18/4/14/3) or cystectomy with residual tumor (n = 3). Five patients received additional cisplatin. Radiation treatment was administered to a total dose of 45-60 Gy. Results: 76.2% completed the planned regimen. Adaptations of treatment were mainly required due to diarrhea. Grade 3/4 toxicities occurred in 15/1 patients. Severe renal toxicities did not occur. 28 patients underwent restaging TUR-BT 6 weeks after radiochemotherapy (complete remission/partial remission/progressive disease: n = 24/3/1). Three patients developed a local recurrence and four distant metastases. Seven patients died from tumor, six of other reasons. Conclusion: Radiochemotherapy with paclitaxel was feasible and this bladder approach needs further investigation to evaluate whether paclitaxel could become a substitute for cisplatin.

ZeitschriftStrahlentherapie und Onkologie
Seiten (von - bis)177-183
PublikationsstatusVeröffentlicht - 04.2007


Untersuchen Sie die Forschungsthemen von „Organ-sparing treatment of advanced bladder cancer: Paclitaxel as a radiosensitizer“. Zusammen bilden sie einen einzigartigen Fingerprint.